ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal tadalafil no prescription chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. This product candidate is a monoclonal antibody that blocks the function of a receptor, found on white blood cells, which plays an early role in the progression of sepsis. Interest and other income tadalafil no prescription was $3. 7 million in the first quarter of 2003, tadalafil no prescription compared to $3. 3 million in tadalafil no prescription the first quarter of 2002. In the first quarter of 2003, Texas Biotechnology agreed to be responsible for all costs and expenses of ICOS-TBC incurred subsequent to December 31, 2002. The tadalafil no prescription company's 50% share of Lilly ICOS' losses increased $7. 3 million from the first quarter of 2002, to tadalafil no prescription $21.
5 million in the first quarter of 2003, reflecting activities associated with the February 2003 commercial launch of Cialis in the European Union. The Phase 1 program showed that IC485 inhibited release of TNF-alpha, a key inflammatory mediator, at doses that were generally well tolerated. On tadalafil no prescription april 22, 2003, the Company entered into an agreement whereby Texas Biotechnology acquired all of the Company's interests in ICOS-TBC for $10. 0 million, with $4. 0 million paid on that date and the balance payable, with interest, in two installments over an 18-month period. Interstitial cystitis affects approximately 700,000 patients in the United States. (2)Impotency tadalafil no prescription information from NIH.
ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, psoriasis, sepsis, and tadalafil no prescription inflammatory diseases.
30, 2003 ICOS Corporation (Nasdaq:ICOS) (the Company) today summarized recent events tadalafil no prescription and 2002 highlights, and released its financial results for the year and the fourth quarter ended December 31, 2002. Revenue from licenses tadalafil no prescription of technology was $6. 6 million tadalafil no prescription in 2002, compared to $30. 8 million in tadalafil no prescription 2001. Regulatory decision for Cialis, which was subsequently delayed and is now anticipated in the second half of 2003. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products. Total operating expenses were $30. 4 million in the first quarter of 2003, compared to $40. 4 million in tadalafil no prescription the first quarter of 2002. Total revenue was $92. 9 tadalafil no prescription million in 2002, compared to $93. 0 million in 2001. Some pills marketed as herbal remedies for erectile dysfunction contain drugs that should be available only by prescription, researchers report. Diabetic gastroparesis is a tadalafil no prescription condition that results in delayed emptying of stomach contents, nausea, vomiting and discomfort in certain patients with diabetes.